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Abstract 
The CEACAM5 gene encodes carcinoembryonic 
antigen (CEA), which was first identified as an 
oncofetal antigen in 1965 in human colon cancer 
tissue extracts. CEA is a heavily glycosylated 
protein that belongs to the CEA-related cell 
adhesion molecule (CEACAM) family of the 
immunoglobulin (Ig) gene superfamily. CEA is 
closely related to CEACAM1, CEACAM3, 
CEACAM4, CEACAM5, CEACAM6, CEACAM7, 
and CEACAM8. CEA is also expressed at low 
levels in normal tissues of epithelial origin in a 
polarized manner and found only at the luminal 
portion of the cell, but not at the basolateral surface. 
CEA in normal tissues is now considered to protect 
the luminal organs of the body from microbial 
infection by binding and trapping infectious 
microorganisms. In contrast, the expression of CEA 
is frequently high in various carcinomas. Cancer 
cells not only lose polarized expression of CEA, but 
also actively cleave CEA from their surface by 
phospholipases, resulting in increased serum 
concentrations of CEA. The serum CEA levels may 
be monitored to detect a response to cancer therapy 
or disease recurrence and serve as a prognostic 
indicator in patients with various cancers, where  
elevated levels indicate a poor prognosis and 
correlate with a reduced overall survival. Cell-
bound CEA has served as a target for tumor 
imaging and various cancer therapies. 
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Identity 
Other names: CEA, CD66e 
HGNC (Hugo): CEACAM5 
Location: 19q13.2 
Local order 
cent ---- CEACAM21 - CEACAMP3 - CEACAM4 
- CEACAM7 - CEACAM5 - CEACAM6 - 
CEACAM3 - CEACAM1 - CEACAMP2 - 
CEACAM8 - CEACAMP1 - CEACAMP5 ---- qter 
Note 
The CEACAM5 gene is classified as a member of 
the CEACAM family (24 genes), which belongs to 
the CEA gene family (35 genes) together with the 
pregnancy-specific glycoprotein (PSG) family (11 
genes). The CEA gene family is a member of the 
immunoglobulin (Ig) supergene family (Thompson 
et al., 1991; Pavlopoulou and Scorilas, 2014). 
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A schematic representation of the chromosomal arrangement of the CEACAM family genes. Main members (CEACAM1, 
CEACAM3, CEACAM4, CEACAM5, CEACAM6 CEACAM7 and CEACAM8) of the CEACAM family are localized in the region of 
the chromosome 19q13.2. 
 
DNA/RNA 
Out of 24 CEACAM family genes, twelve members 
(i.e., CEACAM1, CEACAM3, CEACAM4, 
CEACAM5, CEACAM6, CEACAM7, CEACAM8, 
CEACAM16, CEACAM18, CEACAM19, 
CEACAM20 and CEACAM21) are expressed 
while the other 12 genes are pseudogenes 
(Pavlopoulou and Scorilas, 2014). All the 
CEACAM family genes are localized in the 
19q13.2-19q13.4 region. Although the newly given 
protein names encoded by those active genes are 
the same as the gene names (Beauchemin et al., 
1999), that of CEACAM5 is still CEA because the 
name of CEA has clinically been widely used for a 
long time.  
Splice variants isoforms of CEACAM/CEA have 
been detected, and the resulting protein isoforms 
were not only co-expressed with full-length CEA 
but also co-secreted into the culture medium by 
gastrointestinal cancer cell lines (Hatakeyama et al., 
2013). 
 
(A) Alternative splicing of CEA precursor mRNA leads to the shorter isoforms with different domain structures. Protein-
coding exons (exons 1-9) are shown as yellow boxes; the 3'-untranslated exon 10, the light yellow box. (B) Schematic 
representations of the protein domain structures of the translated CEA transcripts. The black sigmoidal line attached to 
the B3 IgC-like domain indicates a glycosylphosphatidylinositol (GPI) anchor to the plasma membrane (see below). 
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(A) (A) The gene structure and protein domain model of the CEA molecule. CEA encoded by the CEACAM5 gene is 
synthesized as a precursor with a signal peptide (S) followed by 668 amino acids of the putative molecule; the first N-
terminal domain (N domain) is followed by six IgC-like domains (A1, B1, A2, B2, A3, and B3 domains) and the last C-
terminal hydrophobic domain (C domain) (Oikawa et al., 1987). Exons 1 and 9 include a 5'-untranslated region (5'-
UTR) and a 3'-untranslated region (3'-UTR), respectively (Schrewe et al., 1990). (B) Schematic representation of the 
CEA protein structure. CEA is finally anchored to the membrane by the simultaneously occurring proteolysis of the C 
domain and replacement with the GPI anchor immediately after synthesis (Takami et al., 1988). 
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Description 
The CEACAM5 gene, spanning a length of 
approximately 21 kb, consists of 9 exons with a 3'-
non-coding exon (exon 10). 
Transcription 
The primary CEA transcript encodes a protein with 
an Ig variable region (IgV)-like domain, termed N, 
followed by six Ig constant region (IgC)-type 2-like 
domains, termed A1, B1, A2, B2, A3, and B3. In 
some normal and cancer cells, the transcript is 
subjected to alternative splicing, resulting in the 
generation of several CEA isoforms (Hatakeyama 
et al., 2013). The CEA transcript with skipping of 
exons 3-4 encodes the variant with a five-domain 
structure (N-A2-B2-A3-B3 (5D)), while the 
transcript lacking the sequence from the 3' end of 
exon 3 to the 5' end of exon 7 relative to the full-
length transcript contains only three domains (N-
A1-B3 (3D)). 
Pseudogene 
Out of 24 CEACAM family genes, twelve are 
pseudogenes and have been identified in the CEA 




The CEACAM5 gene encodes CEA, which is the 
most widely used tumor marker for the diagnosis 
and monitoring of various cancers (see below). 
CEA is composed of 642 amino acids (a molecular 
mass of approximately 70kDa) and has 28 potential 
N-linked glycosylation sites (Oikawa et al., 1987; 
Nicholson and Stanners, 2007). CEA contains 24-
26 asparagine-linked sugar chains in one molecule 
(Yamashita et al., 1987) and its final molecular 
mass is approximately 180kDa (Thompson et al., 
1991). 
Description 
Among the main CEACAM family members 
(CEACAM1, CEACAM3, CEACAM4, 
CEACAM5, CEACAM6 CEACAM7 and 
CEACAM8), the genes encoding proteins with 
transmembrane domains were assigned the 
CEACAM consecutive numbers 1-4, and the genes 
encoding GPI-anchored proteins including CEA 
were assigned the CEACAM numbers 5-8 
(Beauchemin et al., 1999). 
Expression 
Many CEACAM family proteins, such as 
CEACAM1, CEACAM8, CEACAM6 and 
CEACAM3, are known to be expressed in 
hematopoietic cells (Nagel and Grunert, 1995; 
Baeclay et al., 1997). In contrast, CEA has not been 
detected in hematopoietic cells and shows a more 
limited tissue localization in normal tissues 
including the tongue, esophagus, stomach, 
duodenum, appendix, colon, trachea (Nap et al., 
1988; Kuroki et al., 1981) and lung (Nouwen et al., 
1986). The CEA expression in those organs starts 
during the early fetal period (9-14 weeks) and 
appears to continue throughout one's lifespan (Nap 
et al., 1988). Increased expression of CEA has also 
been observed in various cancers including 
colorectal carcinoma (Jothy et al., 1993), gastric 
carcinoma (Kinugasa et al., 1998), pancreatic 
carcinoma (Shi et al., 1994), gall bladder carcinoma 
(Shi et al., 1994), lung adenocarcinoma (Robbins et 
al., 1993), small cell lung carcinoma (Kim et al., 
1992), breast carcinoma (Cournoyer et al., 1988), 
urinary bladder carcinoma (Shi et al., 1994), 
mucinous ovarian carcinoma (Thompson et al., 
1994), serous ovarian carcinoma (Thompson et al., 
1993) and endometrial adenocarcinoma (Thompson 
et al., 1993). It is usually expressed in 
corresponding metastatic lesions as well, due to its 
involvement in tumor progression and metastasis. 
Localisation 
CEA is localized to columnar epithelial cells and 
goblet cells of the colon, mucous neck cells and 
pyloric mucous cells of the stomach, squamous 
epithelial cells of the tongue, esophagus and cervix, 
secretory epithelia and duct cells of sweat glands 
and epithelial cells of the prostate (Nap et al., 1988; 
Kodera et al., 1993; Prall et al., 1996). Studies 
using immunoelectron microscopy using a specific 
monoclonal antibody for CEA demonstrate that 
CEA is specifically localized to the apical surface 
of mature enterocytes (Ahnen et al., 1982; Baranov 
et al., 1994; Frãngsmyr et al., 1999). No staining is 
seen at the basolateral surfaces of the enterocytes. 
The structure that is specifically stained is the 
apical glycocalyx (= fuzzy coat)/microvillus region 
of the mature enterocytes. The fuzzy coat is made 
up of microvesicles and filaments. The 
microvesicles are formed by the blebbing of 
microvillus membrane and subsequent pinching off. 
The finding that CEA in normal colon is released 
via CEA-coated vesicles agrees with the findings 
which showed that more than 90% of total CEA in 
feces exist in a membrane-bound form and that it 
can be released from the membranes by 
phosphatidylinositol-specific phospholipase C 
(Kuroki et al., 1994; Kinugasa et al., 1994). 
Function 
In vitro studies with tumor cell lines have 
demonstrated that CEA, like other CEA gene 
family members, can act as homophilic and 
heterophilic adhesion molecules when expressed on 
the tumor cell surface (Benchimol et al., 1989; 
Oikawa et al., 1992; Zhou et al., 1993). Therefore, 
in the tumor environment it is possible that CEA 
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plays some role as a contact-mediating device when 
tumor cells are invading new sites. In normal 
physiology, however, it appears unlikely that CEA 
is involved in intercellular adhesion due to their 
apical localization on polarized cells. CEA in 
normal tissues is now considered to protect the 
luminal organs of the body from microbial infection 
by binding and trapping infectious microorganisms. 
Those organs are the colon and perhaps other areas, 
such as the upper alimentary tract, the respiratory 
tract, the urinary bladder, and the skin (sweat 
glands), where the microbial load is a routine event 
(Hammarström, 1999). 
Homology 
The CEACAM5 gene homologue is present in 
primates such as chimpazees, orangutans, macaques 
and marmosets, but not in rodents such as mice and 
rats (Pavlopoulou and Scorilas, 2014). 
Mutations 
As of July 2015, the 245 single-nucleotide 
polymorphisms (SNPs) of the CEACAM gene have 
been included in the NCBI SNP database (dbSNP), 
and there are 19 independent SNPs located within 
the coding region.  However, to date, no clinical 





As described above, CEA is widely expressed not 
only on the surface of tumor cells, but also on 
normal epithelial cells of the luminal organs of the 
body. These facts demonstrate that CEA is no 
longer a carcinoembryonic (oncofetal) antigen, 
rather it should be considered to be a normal tissue 
component with retained/increased expression in 
tumors (Kuroki et al., 1988; Hammarström, 1999). 
The degree of its expression is related to the state of 
differentiation of the normal or tumor cell; highly 
differentiated cells express higher levels of CEA 
(Hammarström, 1999). The localization of CEA in 
normal adult tissues is, however, restricted to the 
apical surface of the epithelial cell membranes 
facing the lumen, so that CEA is not directly 
exposed to the tissue fluid or blood flow. In 
contrast, in tumor tissues that no longer conform to 
the single-layer organization by invading through 
the basement membrane in multicellular arrays, 
CEA is typically localized to all sides of the cell 
surface, directly facing the blood flow or tissue 
fluid (Hammarström, 1999; Khare et al., 2001). As 
the tumor size increases, more CEA will 
accumulate in the blood. Hence, the serum CEA 
levels may be monitored to detect a response to 
anticancer therapy or disease recurrence in various 
cancers, especially in colorectal cancer (Goldstein 
Mitchell, 2005; Locker et al., 2006). 
Immunohistochemical staining of CEA using 
surgically- or biopsy-removed specimens is also 
helpful as a diagnostic aid in patients with various 
cancers (Kuroki et al., 2002). 
Prognosis 
Serum CEA serves as a prognostic indicator in 
patients with various types of cancer, where 
elevated levels indicate a poor prognosis and 
correlate with a reduced overall survival (Duffy, 
2001; Locker et al., 2006). 
To be noted 
The clear contrast of the CEA localization pattern 
between normal tissues and tumor tissues suggests 
that tumor cell-bound CEA may serve as a potential 
target for tumor imaging (Hong et al., 2008) and 
various kinds of cancer therapies using anti-CEA 
monoclonal antibodies or their genes (Khare et al., 
2001; Tanaka et al., 2006; Baek et al., 2011; Peng 
et al., 2012; Kuroki and Shirasu, 2014; Shirasu et 
al, 2014). 
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